3'UTR Shortening In Pulmonary Vascular Disease
肺血管疾病中的 3UTR 缩短
基本信息
- 批准号:10285407
- 负责人:
- 金额:$ 34.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-07-01 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:3&apos Untranslated RegionsAbeta clearanceAccountingAffectAgeAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease patientAlzheimer&aposs disease related dementiaAmyloid beta-ProteinArteriesBlood VesselsBrainBrain DiseasesCerebral Amyloid AngiopathyCerebral cortexCerebrovascular DisordersCerebrovascular systemCerebrumCessation of lifeDataDementiaDepositionDiagnosisDisease ProgressionDrainage procedureEventExperimental ModelsFailureGenesImpairmentIn VitroIntercellular FluidIntracranial HemorrhagesIschemic StrokeLDL-Receptor Related Protein 1LeadLeptomeningesLibrariesLinkLiteratureLungMediatingMemory LossMemory impairmentMusNeurodegenerative DisordersNeurological outcomePathogenesisPathogenicityPathologyPathway interactionsPatientsPolyadenylationPredispositionRNA-Binding ProteinsResearchRisk FactorsRoleSenile PlaquesSmooth Muscle Actin Staining MethodSmooth Muscle MyocytesTestingVascular DiseasesVascular Smooth MuscleVascular remodelingabeta accumulationabeta depositionamyloid formationarteriolebrain tissuecerebrovascularcleavage factorcognitive functioneffective therapyexperimental studyextracellularin vivoinsightlong term memoryneurofibrillary tangle formationnovelpre-clinicalprotein transportstroke outcometranscriptome sequencingvascular smooth muscle cell proliferation
项目摘要
Project Summary
Alzheimer's disease (AD) is a severe neurodegenerative disorder of the brain that affects 35 million people in
the world and 5.5 in the USA. AD is the most common form of dementia accounting for up to 56% of cases
years after diagnosis. Limited therapies are available for AD and they do not delay or halt the progression of
disease and thus new treatments are urgently needed. AD is characterized by the accumulation of cerebral
plaques composed of amyloid-β (Aβ), which is believed to be an early pathogenic event. Most cases of AD are
sporadic and develop after the age of 65 years. Recent studies have indicated an overall impairment in Aβ
clearance, rather than Aβ overproduction to be critical in AD. One of the most common observations in AD,
present in up to 98% of AD patients, is the presence of cerebral amyloid angiopathy (CAA). A recent study has
demonstrated that vascular smooth muscle cells (VSMCs) in the brain are capable of mediating local clearance
of Aβ. CAA is also a major trigger of intracranial hemorrhage a feature of cerebrovascular disease (CVD). This
is significant since there is a large body of literature demonstrating a link between CVD and AD and its
correlation with dementia. Despite the importance of the vasculature in AD, the link between Aβ clearance
through VSMCs and increased CVD leading to dementia is not fully understood. NUDT21, also known as
cleavage factor 25 (CFIm25), is an RNA binding protein that when depleted leads to alternative
polyadenylation (APA) and global 3'UTR shortening. Our research on NUDT21 has revealed that depletion of
NUDT21 is present in the brains of patients with AD and leads to alterations in protein transport and
processing pathways in vascular smooth muscle cells (VSMCs). Our overall hypothesis is that loss of cerebral
vascular smooth muscle NUDT21 disrupts Aβ clearance and predisposes the brain to CVD. This will be tested
in the following Specific Aims: 1- Evaluate the role of NUDT21 loss and 3'UTR landscape in AD; 2- Determine
whether NUDT21 depletion promotes CAA and 3- Assess whether NUDT21 depletion exacerbates
cerebrovascular disease (CVD). Successful completion of these experiments is expected to reveal new
insights into the pathogenesis of AD and AD related dementias (ADRD). Specifically, this proposal aims to
uncover novel pathways related to vascular Aβ clearance and predisposition to CVD linked by APA induced by
loss of NUDT1. These concepts have not been fully explored in AD thus; this proposal has the potential to
stimulate additional activity leading to progress on AD and ADRD.
项目摘要
阿尔茨海默病(AD)是一种严重的大脑神经退行性疾病,在美国有3500万人受到影响
世界和美国分别为5.5和5.5。AD是最常见的痴呆症形式,占痴呆症病例的56%
在确诊数年后。阿尔茨海默病的治疗方法有限,它们不会延缓或阻止AD的进展
因此迫切需要新的治疗方法。AD的特点是脑积聚
斑块由淀粉样蛋白-β(Aβ)组成,被认为是一种早期致病事件。大多数AD病例是
散发性,65岁以后发展。最近的研究表明,β的整体损害
在AD中,关键是清理,而不是β生产过剩。在AD中最常见的观察之一,
高达98%的AD患者存在脑淀粉样血管病变(CAA)。最近的一项研究表明
证明大脑中的血管平滑肌细胞(VSMCs)能够介导局部清除
一个β的人。CAA也是脑血管疾病(CVD)的特征之一--颅内出血的主要诱因。这
意义重大,因为有大量文献表明心血管疾病和AD之间的联系,以及
与痴呆症的相关性。尽管血管系统在AD中很重要,但β清除之间的联系
通过VSMCs和增加的CVD导致痴呆的机制还不完全清楚。NUDT21,也称为
裂解因子25(CFIm25)是一种RNA结合蛋白,当耗尽时会导致替代
多聚腺苷酸化(APA)和全球3‘非编码区缩短。我们对NUDT21的研究表明,
NUDT21存在于AD患者的大脑中,并导致蛋白质转运和
血管平滑肌细胞(VSMCs)的加工途径。我们的总体假设是大脑的丧失
血管平滑肌NUDT21破坏β清除,使大脑易患脑血管病。这将会被测试
在以下具体目标中:1-评估NUDT21丢失和3‘UTR景观在AD中的作用;2-确定
NUDT21枯竭是否促进CAA和3-评估NUDT21枯竭是否加剧
脑血管疾病(CVD)。这些实验的成功完成有望揭示出新的
对AD和AD相关痴呆(ADRD)发病机制的洞察。具体地说,这项建议旨在
发现与血管Aβ清除相关的新途径和与APA相关的心血管疾病易感性
失去NUDT1。因此,这些概念在AD中还没有得到充分的探讨;本提案有可能
刺激额外的活动,从而在AD和ADRD方面取得进展。
项目成果
期刊论文数量(16)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets.
- DOI:10.3390/ijms21218081
- 发表时间:2020-10-29
- 期刊:
- 影响因子:5.6
- 作者:Karmouty-Quintana H;Thandavarayan RA;Keller SP;Sahay S;Pandit LM;Akkanti B
- 通讯作者:Akkanti B
Cleavage stimulating factor 64 depletion mitigates cardiac fibrosis through alternative polyadenylation.
裂解刺激因子64耗竭可通过替代聚腺苷酸化来减轻心脏纤维化。
- DOI:10.1016/j.bbrc.2022.01.093
- 发表时间:2022-03-15
- 期刊:
- 影响因子:3.1
- 作者:Neupane, Rahul;Youker, Keith;Yalamanchili, Hari Krishna;Cieslik, Katarzyna A.;Karmouty-quintana, Harry;Guha, Ashrith;Thandavarayan, Rajarajan A.
- 通讯作者:Thandavarayan, Rajarajan A.
Hyaluronan in the pathogenesis of acute and post-acute COVID-19 infection.
透明质酸在急性和急性后共证感染的发病机理中。
- DOI:10.1016/j.matbio.2023.02.001
- 发表时间:2023-03
- 期刊:
- 影响因子:6.9
- 作者:Barnes, Henry W.;Demirdjian, Sally;Haddock, Naomi L.;Kaber, Gernot;Martinez, Hunter A.;Nagy, Nadine;Karmouty-Quintana, Harry;Bollyky, Paul L.
- 通讯作者:Bollyky, Paul L.
Implication of Ventricular Assist Devices in Extracorporeal Membranous Oxygenation Patients Listed for Heart Transplantation.
心室辅助装置对接受心脏移植的体外膜氧合患者的影响。
- DOI:10.3390/jcm8050572
- 发表时间:2019
- 期刊:
- 影响因子:3.9
- 作者:Guha,Ashrith;Hannawi,Bashar;Cruz-Solbes,AnaS;Nguyen,DucT;Bruckner,BrianA;Trachtenberg,Barry;Graviss,EdwardA;Bhimaraj,Arvind;Park,Myung;Hussain,Imad;MacGillivray,ThomasE;Suarez,ErikE;Estep,JerryD
- 通讯作者:Estep,JerryD
Crystal Deposits in Macrophages and Distal Lung Remodeling: A Tale of Aging in SFTPC-Deficient Mice.
巨噬细胞中的晶体沉积和远端肺重塑:SFTPC 缺陷小鼠的衰老故事。
- DOI:10.1165/rcmb.2020-0018ed
- 发表时间:2020
- 期刊:
- 影响因子:6.4
- 作者:Weng,Tingting;Karmouty-Quintana,Harry
- 通讯作者:Karmouty-Quintana,Harry
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Harry Karmouty-Quintana其他文献
Harry Karmouty-Quintana的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Harry Karmouty-Quintana', 18)}}的其他基金
Sineoculis Homeobox Homolog 1 (Six1) in Pulmonary Fibrosis
肺纤维化中的 Sineoculis 同源框同源物 1 (Six1)
- 批准号:
10181872 - 财政年份:2021
- 资助金额:
$ 34.08万 - 项目类别:
Sineoculis Homeobox Homolog 1 (Six1) in Pulmonary Fibrosis
肺纤维化中的 Sineoculis 同源框同源物 1 (Six1)
- 批准号:
10371174 - 财政年份:2021
- 资助金额:
$ 34.08万 - 项目类别:
Sineoculis Homeobox Homolog 1 (Six1) in Pulmonary Fibrosis
肺纤维化中的 Sineoculis 同源框同源物 1 (Six1)
- 批准号:
10589121 - 财政年份:2021
- 资助金额:
$ 34.08万 - 项目类别:
Sineoculis Homeobox Homolog 1 (Six1) in Pulmonary Fibrosis
肺纤维化中的 Sineoculis 同源框同源物 1 (Six1)
- 批准号:
10756602 - 财政年份:2021
- 资助金额:
$ 34.08万 - 项目类别:
3'UTR Shortening in Pulmonary Vascular Disease
肺血管疾病中的 3UTR 缩短
- 批准号:
9921481 - 财政年份:2017
- 资助金额:
$ 34.08万 - 项目类别:
相似海外基金
Impact of alternative polyadenylation of 3'-untranslated regions in the PI3K/AKT cascade on microRNA
PI3K/AKT 级联中 3-非翻译区的替代多聚腺苷酸化对 microRNA 的影响
- 批准号:
573541-2022 - 财政年份:2022
- 资助金额:
$ 34.08万 - 项目类别:
University Undergraduate Student Research Awards
How do untranslated regions of cannabinoid receptor type 1 mRNA determine receptor subcellular localisation and function?
1 型大麻素受体 mRNA 的非翻译区如何决定受体亚细胞定位和功能?
- 批准号:
2744317 - 财政年份:2022
- 资助金额:
$ 34.08万 - 项目类别:
Studentship
MICA:Synthetic untranslated regions for direct delivery of therapeutic mRNAs
MICA:用于直接递送治疗性 mRNA 的合成非翻译区
- 批准号:
MR/V010948/1 - 财政年份:2021
- 资助金额:
$ 34.08万 - 项目类别:
Research Grant
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10019570 - 财政年份:2019
- 资助金额:
$ 34.08万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10223370 - 财政年份:2019
- 资助金额:
$ 34.08万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10455108 - 财政年份:2019
- 资助金额:
$ 34.08万 - 项目类别:
Synergistic microRNA-binding sites, and 3' untranslated regions: a dialogue of silence
协同的 microRNA 结合位点和 3 非翻译区:沉默的对话
- 批准号:
255762 - 财政年份:2012
- 资助金额:
$ 34.08万 - 项目类别:
Operating Grants
Analysis of long untranslated regions in Nipah virus genome
尼帕病毒基因组长非翻译区分析
- 批准号:
20790351 - 财政年份:2008
- 资助金额:
$ 34.08万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Search for mRNA elements involved in the compatibility between 5' untranslated regions and coding regions in chloroplast translation
寻找参与叶绿体翻译中 5 非翻译区和编码区之间兼容性的 mRNA 元件
- 批准号:
19370021 - 财政年份:2007
- 资助金额:
$ 34.08万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Post-transcriptional Regulation of PPAR-g Expression by 5'-Untranslated Regions
5-非翻译区对 PPAR-g 表达的转录后调控
- 批准号:
7131841 - 财政年份:2006
- 资助金额:
$ 34.08万 - 项目类别:














{{item.name}}会员




